Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study
Open Access
- 21 June 2012
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 119 (25), 6005-6015
- https://doi.org/10.1182/blood-2011-12-396556
Abstract
The SHIELD program for Hodgkin lymphoma in patients 60 years of age or older, prospectively evaluated clinical features and outcome in a large patient cohort (n = 175). The central element was a phase 2 study of VEPEMB chemotherapy (n = 103, median age 73 years) incorporating comorbidity assessment. A total of 72 other patients were treated off-study but registered prospectively and treated concurrently with: ABVD (n = 35); CLVPP (n = 19), or other (n = 18). Of VEPEMB patients, 31 had early-stage disease (stage 1A/2A) and received VEPEMB 3 times plus radiotherapy. Median follow-up was 36 months. Complete remission (CR) rate (intention-to-treat) was 74% and 3-year overall survival (OS) and progression-free survival (PFS) were 81% and 74%, respectively. A total of 72 patients had advanced-stage disease (stage 1B/2B/3 or 4) and received VEPEMB 6 times. CR rate was 61% with 3-year OS and PFS of 66% and 58%, respectively. Of patients achieving CR, 13% with early-stage and 5% with advanced-stage disease progressed. Overall treatment-related mortality was 7%. In patients treated with curative intent with VEPEMB, ABVD, and CLVPP (n = 157), CR linked to several factors in univariate analysis. In a Cox regression model only, obtaining CR remained significant for OS and CR plus comorbidity and age for PFS. RS-EBV status had no significant effect on outcome.Keywords
This publication has 18 references indexed in Scilit:
- Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphomaBlood, 2011
- Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)Blood, 2010
- Hodgkin lymphoma in the elderly: A clinical review of treatment and outcome, past, present and futureCritical Reviews in Oncology/Hematology, 2009
- A web-based study concept designed to progress clinical research for ‘orphan’ disease areas in haematological oncology in the elderly: The SHIELD programmeCritical Reviews in Oncology/Hematology, 2007
- Prognostic Importance of Comorbidity in a Hospital-Based Cancer RegistryJAMA, 2004
- VEPEMB in elderly Hodgkin’s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) studyAnnals Of Oncology, 2004
- Hodgkin's disease in the elderly: a population‐based studyBritish Journal of Haematology, 2002
- Hodgkin's disease in the elderly: current status and future directionsAnnals Of Oncology, 2002
- Chemotherapy of Advanced Hodgkin's Disease with MOPP, ABVD, or MOPP Alternating with ABVDNew England Journal of Medicine, 1992
- Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily LivingThe Gerontologist, 1969